• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Thoratec’s new study, $30M buyback can’t stave off Wall Street exodus after dismal Q2

Thoratec’s new study, $30M buyback can’t stave off Wall Street exodus after dismal Q2

August 7, 2014 By Arezu Sarvestani

New study, $30M buyback can't save Thoratec from Wall Street exodus after dismal Q2

Circulatory devices maker Thoratec (NSDQ:THOR) took a major hit yesterday as a bleak 2nd-quarter reports and a lowered outlook on the year sent its stock into a nosedive.

Company leadership called the quarter "disappointing," but advised that near-term headwinds would ebb and that the long-term outlook remains strong for Thoratec. Wall Street’s response wasn’t so optimistic.

Thoratec’s stock dropped more than 26% in after-hours trading after the company reported a 25% decline in profits on a 10% decline in sales during its 2nd quarter. THOR shares were trading at $24.02 at around 8 p.m. EST, the lowest they’ve sold for in at least a year.

Even news of a $30 million share repurchase and the launch of a new clinical trial in support of European regulatory approval couldn’t stem the Wall Street exodus.

Alongside its Q2 earnings, Thoratec announced that it entered into an accelerated share repurchase program, slated to begin in the next few days, to quickly reclaim $30 million as part of a larger $200 million buyback launched in December 2013. The measure was intended to demonstrate that the company still believes in itself, president & CEO Gary Burbach said in prepared remarks.

"This commitment to capital deployment reflects our ongoing conviction in the long term opportunities in our business," Burbach said in prepared remarks. "Furthermore, our strong financial position will enable us to evaluate the potential for additional capital deployment in a consistently disciplined manner that allows for meeting our top priorities of internal growth and strategic initiatives."

In a separate notice Thoratec also announced last night that it launched a new clinical trial for its HeartMate Percutaneous Heart Pump (PHP) in hopes of winning over European regulators. The next-generation device is designed to be smaller and perform better than earlier devices, the company said.

"We are excited to begin the CE Mark Clinical Trial for HeartMate PHP and look forward to successful execution of this important clinical study," Burbach said in that announcement.  "The HeartMate PHP addresses a significant clinical need for acute mechanical circulatory support and represents a new area of future growth for Thoratec," he added.

Commitment and excitement weren’t enough to keep Thoratec’s shares afloat. The stock began sinking before the end of the day, closing down by 1.5% yesterday before dropping another 26.3% by late evening.

In total the company reported profits of $17.4 million, or 30¢ per diluted share, on sales of $118.1 million during the 3 months ended June 28, 2014. That compared with profits of $23.2 million, or 40¢ per share, on sales of $130.5 million during the same period last year. Excluding special items, adjusted earnings amounted to 43¢ per share, right on target with analysts’ expectations.

Thoratec also lowered its guidance for the rest of the year, now expecting revenue in the range of $455 million to $470 million, down from previous projections of $520 million to $535 million. Adjusted earnings are now estimated at $1.25 to $1.35 per share, down from $1.72 to $1.82 per share. The figures did not take into account the company’s recent $75 million acquisition of Apica Cardiovascular and its transapical access technology.

Pleasanton, Calif.-based Thoratec faced some significant hurdles in its 2nd quarter, including the ongoing effects of a New England Journal of Medicine report published last year detailing sharp increases in the rate of blood clots associated with the company’s HeartMate II implantable heart pump.

"We believe perceptions about pump thrombosis since the late 2013 New England Journal of Medicine article along with greater scrutiny of clinical outcomes overall continues to be the largest factor impacting our business on a worldwide basis," Burbach said during yesterday’s conference call with analysts. "While we expected that this would be a headwind during the 1st half of the year, now, clearly, the impact is persisting longer than expected."

Filed Under: MassDevice Earnings Roundup, News Well, Structural Heart, Wall Street Beat Tagged With: 2014, Clinical Trials, Q2, Thoratec Corp.

In case you missed it

  • How safe is health information after the overturning of Roe?
  • Smith+Nephew opens new plant in Malaysia
  • BD launches combination COVID-19, flu, RSV diagnostic test
  • Zimmer Biomet creates independent nonprofit organization to reduce health disparities
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
  • Nasdaq grants Titan Medical 180-day extension to regain compliance
  • Aerin Medical reports positive 4-year results for VivAer treatment
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
  • How medical device companies are responding to abortion bans
  • Clarius partners with ImaCor on handheld hemodynamic ultrasound tech
  • Withings appoints Elizabeth Coleon as chief marketing officer
  • Visby Medical raises $135M in expanded Series E
  • Boston Scientific to build new plant outside Atlanta
  • NovaXS unveils prototype for smart, needle-free drug delivery device
  • ResMed names Lucile Blaise as new Sleep & Respiratory Care leader
  • SpineX enrolls first patient in spinal neuromodulation technology trial
  • GE Healthcare’s Carescape ventilator battery recall is Class I

RSS From Medical Design & Outsourcing

  • How safe is health information after the overturning of Roe?
    The U.S. Department of Health and Human Services today issued guidance meant to better protect women’s health information as state abortion bans kick in after the U.S. Supreme Court’s overturning of Roe v. Wade. Despite the HHS actions, women may still wonder whether their health information is entirely safe going forward — a potential challenge… […]
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
    New evidence is showing that COVID-19 may increase a person’s risk of diabetes, but it could be years until we know for sure. In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said. Walker recently spoke with Medical Design & Outsourcing to discuss the San Diego-based diabetes device developer’s… […]
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
    Blackrock Neurotech and the University of Pittsburgh’s Rehab Neural Engineering Labs (Pitt RNEL) are working together on the first portable brain-computer interface (BCI) to allow patients to participate in research trials from home. A Blackrock representative said it’s the final step as the company prepares to launch its first commercial product early next year. Salt… […]
  • How medical device companies are responding to abortion bans
    Days after the U.S. Supreme Court’s decision to overturn Roe v. Wade’s protection of abortion rights, medical device companies are among those reassuring workers about healthcare access. Corporate communications to employees and the public at large come as trigger laws in nearly half of the states outlaw abortion immediately. Some medtech companies are not using… […]
  • Philips updates on testing results for recalled ventilators
    Royal Philips (NYSE:PHG) says only a small portion of returned respiratory devices displayed the sound abatement foam degradation that sparked a massive recall. Repeated ozone cleaning may have made the problem worse. Those were some of the major takeaways from an update Philips provided today on a comprehensive test and research program it implemented after its… […]
  • ResMed names Lucile Blaise as new Sleep & Respiratory Care leader
    Lucile Blaise will be the new president of ResMed’s Sleep & Respiratory Care business starting July 1, ResMed (NYSE: RMD) said today. She replaces Jim Hollingshead, who became president and CEO of Insulet (Nasdaq:PODD) on June 1. ResMed President and COO Rob Douglas is serving as interim president of the Sleep & Respiratory Care during… […]
  • Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
    Cardinal Health (NYSE: CAH) today started air delivery of pharmaceutical products and medical supplies via Zipline drone in North Carolina. San Francisco-based Zipline won FAA Part 135 air carrier certification for the long-range flights earlier this month. The company flew its first commercial deliveries on June 22 with an initial 16-nautical-mile flight. The flights starting… […]
  • Boston Centerless opens manufacturing plant in Indiana
    Boston Centerless announced today that it opened a second manufacturing plant in Fort Wayne, Indiana. Woburn, Massachusetts-based Boston Centerless said in a news release that the latest expansion for the supplier of precision ground bar materials for close tolerance CNC Swiss machining applications represents continued robust growth in key market segments in the Midwest and… […]
  • Dymax strikes new partnership with Quantum Systems
    Rapid curing materials and equipment manufacturer Dymax today announced a new sales partnership with Quantum Systems. Torrington, Connecticut-based Dymax said in a news release that Quantum, with its offices in Arizona as well as Sonora and Baja, Mexico, will focus its efforts on promoting and supporting the sales of Dymax light-curing solutions to the medical,… […]
  • Researchers develop wearable robotic exomuscle system
    ETH Zurich researchers have redefined the muscle shirt. Marie Georgarakis, a former doctoral student at ETH Zurich’s Sensory Motor Systems Lab, is the creator of the Myoshirt, a wearable, textile robotic device that helps users lift their arms and reach. A motorized cable works like an artificial tendon, directed by sensors and an algorithm to… […]
  • They said it at DeviceTalks Boston
    Medtech insiders convened at DeviceTalks Boston 2022 in May to discuss device design, innovation and trends shaping the industry now and in the years and decades ahead. Here are some of the most quotable insights from panelists and speakers at our live event. And make sure to save the date — and save your seat… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS